{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:18:39Z","timestamp":1792091919610,"version":"4.4.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-HS202102-0177"],"award-info":[{"award-number":["Y-HS202102-0177"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-MSDZD2021-0169"],"award-info":[{"award-number":["Y-MSDZD2021-0169"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["YBMS2019-071"],"award-info":[{"award-number":["YBMS2019-071"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008081","name":"Southeast University","doi-asserted-by":"publisher","award":["4024002312"],"award-info":[{"award-number":["4024002312"]}],"id":[{"id":"10.13039\/501100008081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014980","name":"Wannan Medical College","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014980","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.actbio.2023.10.024","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T11:38:45Z","timestamp":1698320325000},"page":"365-377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Hollow Cu2MoS4 nanoparticles loaded with immune checkpoint inhibitors reshape the tumor microenvironment to enhance immunotherapy for pancreatic cancer"],"prefix":"10.1016","volume":"173","author":[{"given":"Zhipeng","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxue","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8902-0764","authenticated-orcid":false,"given":"Hongping","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9791","key":"10.1016\/j.actbio.2023.10.024_bib0001","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","article-title":"Pancreatic cancer","volume":"378","author":"Vincent","year":"2011","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.actbio.2023.10.024_bib0002","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"G. Canadian Cancer Trials, G.I.P.G. the unicancer, FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.actbio.2023.10.024_bib0003","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMra0901557","article-title":"Pancreatic cancer","volume":"362","author":"Hidalgo","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.actbio.2023.10.024_bib0004","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.2147\/OTT.S105587","article-title":"Onivyde for the therapy of multiple solid tumors","volume":"9","author":"Zhang","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"26","key":"10.1016\/j.actbio.2023.10.024_bib0005","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"6382","key":"10.1016\/j.actbio.2023.10.024_bib0006","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"328","key":"10.1016\/j.actbio.2023.10.024_bib0007","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.actbio.2023.10.024_bib0008","doi-asserted-by":"crossref","DOI":"10.21037\/apc.2018.11.01","article-title":"Immune defects in pancreatic cancer","volume":"1","author":"Zheng","year":"2018","journal-title":"Ann. Pancreat. Cancer"},{"key":"10.1016\/j.actbio.2023.10.024_bib0009","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejphar.2014.07.041","article-title":"Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer","volume":"741","author":"de Sousa Cavalcante","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.actbio.2023.10.024_bib0010","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.3389\/fimmu.2018.01878","article-title":"Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: current limitations and future options","volume":"9","author":"Kabacaoglu","year":"2018","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.actbio.2023.10.024_bib0011","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/cmi.2008.46","article-title":"Roles of chemokine receptor 4 (CXCR4) and chemokine ligand 12 (CXCL12) in metastasis of hepatocellular carcinoma cells","volume":"5","author":"Liu","year":"2008","journal-title":"Cell Mol. Immunol."},{"issue":"4","key":"10.1016\/j.actbio.2023.10.024_bib0012","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s10555-010-9256-x","article-title":"CXCL12\/CXCR4\/CXCR7 chemokine axis and cancer progression","volume":"29","author":"Sun","year":"2010","journal-title":"Cancer Metastasis Rev."},{"issue":"3","key":"10.1016\/j.actbio.2023.10.024_bib0013","doi-asserted-by":"crossref","first-page":"C987","DOI":"10.1152\/ajpcell.00406.2006","article-title":"Stroma-derived factor (SDF-1\/CXCL12) and human tumor pathogenesis","volume":"292","author":"Kryczek","year":"2007","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.actbio.2023.10.024_bib0014","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.pharmthera.2017.05.012","article-title":"Emerging roles of the CXCL12\/CXCR4 axis in pancreatic cancer progression and therapy","volume":"179","author":"Sleightholm","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.actbio.2023.10.024_bib0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ctrv.2019.06.005","article-title":"Checkpoint inhibitors in pancreatic cancer","volume":"78","author":"Henriksen","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.actbio.2023.10.024_bib0016","article-title":"The immune microenvironment and progression of immunotherapy and combination therapeutic strategies for hepatocellular carcinoma","volume":"7","author":"Feng","year":"2021","journal-title":"Hepatoma Res."},{"issue":"46","key":"10.1016\/j.actbio.2023.10.024_bib0017","doi-asserted-by":"crossref","first-page":"28960","DOI":"10.1073\/pnas.2013644117","article-title":"CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response","volume":"117","author":"Biasci","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.actbio.2023.10.024_bib0018","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/gutjnl-2016-311585","article-title":"IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer","volume":"67","author":"Mace","year":"2018","journal-title":"Gut"},{"issue":"30","key":"10.1016\/j.actbio.2023.10.024_bib0019","doi-asserted-by":"crossref","first-page":"12966","DOI":"10.1039\/D1NR03288G","article-title":"Combining PD-L1 inhibitors with immunogenic cell death triggered by chemo-photothermal therapy via a thermosensitive liposome system to stimulate tumor-specific immunological response","volume":"13","author":"Yu","year":"2021","journal-title":"Nanoscale"},{"issue":"3","key":"10.1016\/j.actbio.2023.10.024_bib0020","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.actbio.2023.10.024_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/cells9092102","article-title":"Nano-enhanced cancer immunotherapy: immunology encounters nanotechnology","volume":"9","author":"Bockamp","year":"2020","journal-title":"Cells"},{"issue":"20","key":"10.1016\/j.actbio.2023.10.024_bib0022","doi-asserted-by":"crossref","first-page":"eaaz9240","DOI":"10.1126\/sciadv.aaz9240","article-title":"Targeting pulmonary tumor microenvironment with CXCR4-inhibiting nanocomplex to enhance anti-PD-L1 immunotherapy","volume":"6","author":"Li","year":"2020","journal-title":"Sci. Adv."},{"issue":"12","key":"10.1016\/j.actbio.2023.10.024_bib0023","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1016\/j.apsb.2022.11.001","article-title":"Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy","volume":"12","author":"Xu","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.actbio.2023.10.024_bib0024","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12951-021-01017-w","article-title":"Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells","volume":"19","author":"Xu","year":"2021","journal-title":"J. Nanobiotechnol."},{"issue":"4","key":"10.1016\/j.actbio.2023.10.024_bib0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1208\/s12248-020-00467-8","article-title":"Nano-delivery of gemcitabine derivative as a therapeutic strategy in a desmoplastic KRAS mutant pancreatic cancer","volume":"22","author":"Das","year":"2020","journal-title":"AAPS J."},{"issue":"11","key":"10.1016\/j.actbio.2023.10.024_bib0026","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202007149","article-title":"Metformin mediated PD-L1 downregulation in combination with photodynamic-immunotherapy for treatment of breast cancer","volume":"31","author":"Hu","year":"2021","journal-title":"Adv. Funct. Mater."},{"issue":"1","key":"10.1016\/j.actbio.2023.10.024_bib0027","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40824-022-00309-y","article-title":"Efficiently targeted therapy of glioblastoma xenograft via multifunctional biomimetic nanodrugs","volume":"26","author":"Yao","year":"2022","journal-title":"Biomater. Res."},{"issue":"8","key":"10.1016\/j.actbio.2023.10.024_bib0028","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1158\/1078-0432.CCR-10-2636","article-title":"CXCL12 (SDF1alpha)-CXCR4\/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?","volume":"17","author":"Duda","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.actbio.2023.10.024_bib0029","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3727\/096368916X693563","article-title":"A novel CXCR4 antagonist cx549 induces neuroprotection in stroke brain","volume":"26","author":"Wu","year":"2017","journal-title":"Cell Transplant."},{"key":"10.1016\/j.actbio.2023.10.024_bib0030","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.biomaterials.2015.07.035","article-title":"CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer","volume":"67","author":"Gao","year":"2015","journal-title":"Biomaterials"},{"issue":"22","key":"10.1016\/j.actbio.2023.10.024_bib0031","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202100715","article-title":"Synergy of immunostimulatory genetherapy with immune checkpoint blockade motivates immune response to eliminate cancer","volume":"31","author":"Yu","year":"2021","journal-title":"Adv. Funct. Mater."},{"issue":"2","key":"10.1016\/j.actbio.2023.10.024_bib0032","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/jbm.b.34698","article-title":"Inhibition of programmed death-1 decreases neointimal hyperplasia after patch angioplasty","volume":"109","author":"Bai","year":"2021","journal-title":"J. Biomed. Mater. Res. B"},{"key":"10.1016\/j.actbio.2023.10.024_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111955","article-title":"Immune checkpoint programmed death-1 mediates abdominal aortic aneurysm and pseudoaneurysm progression","volume":"142","author":"Sun","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.actbio.2023.10.024_bib0034","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.actbio.2023.10.024_bib0035","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13046-019-1153-8","article-title":"Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment","volume":"38","author":"Looi","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.actbio.2023.10.024_bib0036","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.actbio.2023.10.024_bib0037","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1182\/blood-2006-12-062422","article-title":"Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells","volume":"110","author":"Goldberg","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.actbio.2023.10.024_bib0038","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1038\/s41467-020-18244-8","article-title":"IL-20 antagonist suppresses PD-L1 expression and prolongs survival in pancreatic cancer models","volume":"11","author":"Lu","year":"2020","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.actbio.2023.10.024_bib0039","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr. Opin. Immunol."},{"issue":"7","key":"10.1016\/j.actbio.2023.10.024_bib0040","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1158\/1078-0432.CCR-06-2746","article-title":"Clinical significance and therapeutic potential of the programmed death-1 ligand\/programmed death-1 pathway in human pancreatic cancer","volume":"13","author":"Nomi","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.actbio.2023.10.024_bib0041","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a Phase 2 randomized clinical trial","volume":"5","author":"O'Reilly","year":"2019","journal-title":"JAMA Oncol."},{"issue":"13","key":"10.1016\/j.actbio.2023.10.024_bib0042","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2015433118","article-title":"A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment","volume":"118","author":"Song","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.actbio.2023.10.024_bib0043","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202002147","article-title":"Combination chemo-immunotherapy for pancreatic cancer using the immunogenic effects of an irinotecan silicasome nanocarrier plus anti-PD-1","volume":"8","author":"Liu","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.actbio.2023.10.024_bib0044","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.actbio.2023.10.024_bib0045","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.cytogfr.2013.05.001","article-title":"Crosstalk between ER stress and immunogenic cell death","volume":"24","author":"Kepp","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"issue":"6","key":"10.1016\/j.actbio.2023.10.024_bib0046","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.actbio.2023.10.024_bib0047","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.biomaterials.2016.06.032","article-title":"Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy","volume":"102","author":"Zhao","year":"2016","journal-title":"Biomaterials"},{"issue":"8","key":"10.1016\/j.actbio.2023.10.024_bib0048","doi-asserted-by":"crossref","first-page":"107376","DOI":"10.1016\/j.isci.2023.107376","article-title":"STING-IRG1 inhibits liver metastasis of colorectal cancer by regulating the polarization of tumor-associated macrophages","volume":"26","author":"Liu","year":"2023","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.actbio.2023.10.024_bib0049","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1053\/j.gastro.2015.04.010","article-title":"Exclusion of T cells from pancreatic carcinomas in mice is regulated by Ly6C(low) F4\/80(+) extratumoral macrophages","volume":"149","author":"Beatty","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.actbio.2023.10.024_bib0050","first-page":"3","article-title":"The immune microenvironment and progression of immunotherapy and combination therapeutic strategies for hepatocellular carcinoma","volume":"7","author":"Feng","year":"2021","journal-title":"Hepatoma Res."},{"issue":"8","key":"10.1016\/j.actbio.2023.10.024_bib0051","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221169","article-title":"Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: enhancing diagnostic accuracy","volume":"14","author":"Kruger","year":"2019","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.actbio.2023.10.024_bib0052","first-page":"5488","article-title":"Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia","volume":"60","author":"Cahlin","year":"2000","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.actbio.2023.10.024_bib0053","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/jid.2013.437","article-title":"SECTM1 produced by tumor cells attracts human monocytes via CD7-mediated activation of the PI3K pathway","volume":"134","author":"Wang","year":"2014","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.actbio.2023.10.024_bib0054","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.biomaterials.2016.09.034","article-title":"Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment","volume":"112","author":"Wang","year":"2017","journal-title":"Biomaterials"}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706123006232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706123006232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:13:26Z","timestamp":1761675206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706123006232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":54,"alternative-id":["S1742706123006232"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2023.10.024","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hollow Cu2MoS4 nanoparticles loaded with immune checkpoint inhibitors reshape the tumor microenvironment to enhance immunotherapy for pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2023.10.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}